High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi

Marah G. Chibwana[1§], Khuzwayo C. Jere[1,2§], Raphael Kamn'gona[1], Jonathan Mandolo[1], Vincent Katunga-Phiri[1], Dumizulu Tembo[1], Ndaona Mitole[1], Samantha Musasa[3], Simon Sichone[1], Agness Lakudzala[1], Lusako Sibale[1], Prisca Matambo[1], Innocent Kadwala[1], Rachel L. Byrne[5], Alice Mbewe[1], Ben Morton[1,5], Chimota Phiri[4], Jane Mallewa[3], Henry C Mwandumba[1,5], Emily R. Adams[5], Stephen B. Gordon[1,5]*, Kondwani C. Jambo[1,5#*]

[1] Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi.

[2] Centre for Global Vaccine Research, Institute of Infection, Veterinary Ecological Sciences, University of Liverpool, Liverpool, UK.

[3] Department of Medicine, College of Medicine, University of Malawi, Blantyre, Malawi.

[4] Ministry of Health, Queen Elizabeth Central Hospital, Blantyre, Malawi

[5] Liverpool School of Tropical Medicine, L3 5QA, Liverpool, United Kingdom.

[#]**Corresponding author:** Viral Immunology Research Group, Malawi-Liverpool-Wellcome Trust Clinical Research Programme, P.O Box 30096, Blantyre 3, Malawi. Tel : 01 874 628 Fax : +265 1 875 774. ORCID ID: 0000-0002-3195-2210

Email: kjambo@mlw.mw

[§]Authors contributed equally.

*Joint senior authors

Running Head: High SARS-CoV-2 seroprevalence in Urban Malawi

Key Words: SARS-CoV-2, COVID-19, Malawi, Seroprevalence, IgG

Abstract

Background

In low-income countries, like Malawi, important public health measures including social distancing or a lockdown, have been challenging to implement owing to socioeconomic constraints, leading to predictions that the COVID-19 pandemic would progress rapidly. However, due to limited capacity to test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, there are no reliable estimates of the true burden of infection and death. We, therefore, conducted a SARS-CoV-2 serosurvey amongst health care workers (HCW) in Blantyre city to estimate the cumulative incidence of SARS-CoV-2 infection in urban Malawi.

Methods

Five hundred otherwise asymptomatic HCWs were recruited from Blantyre City (Malawi) from 22nd May 2020 to 19th June 2020 and serum samples were collected all participants. A commercial ELISA was used to measure SARS-CoV-2 IgG antibodies in serum. We run local negative samples (2018 - 2019) to verify the specificity of the assay. To estimate the seroprevalence of SARS CoV-2 antibodies, we adjusted the proportion of positive results based on local specificity of the assay.

Results

Eighty-four participants tested positive for SARS-CoV-2 antibodies. The HCW with a positive SARS-CoV-2 antibody result came from different parts of the city. The adjusted seroprevalence of SARS-CoV-2 antibodies was 12.3% [CI 9.0–15.7]. Using age-stratified infection fatality estimates reported from elsewhere, we found that at the observed adjusted seroprevalence, the number of predicted deaths was 8 times the number of reported deaths.

Conclusion

The high seroprevalence of SARS-CoV-2 antibodies among HCW and the discrepancy in the predicted versus reported deaths, suggests that there was early exposure but slow progression of COVID-19 epidemic in urban Malawi. This highlights the urgent need for development of locally parameterised mathematical models to more accurately predict the trajectory of the epidemic in sub-Saharan Africa for better evidence-based policy decisions and public health response planning.

Introduction

Coronavirus Disease 2019 (COVID-19) has had a dramatic impact worldwide, with high mortality in Asia, Europe and Americas (1). Africa reported its first COVID-19 case on 14th February 2020 (2). Due to poor socio-economic conditions, high HIV prevalence, an increase in non-communicable diseases and challenged health system infrastructure, it was predicted that the African pandemic would progress rapidly. As of 16th July 2020, however, the number of COVID-19 cases was 665,522 and deaths 14,434 (1, 2), much lower than predicted by mathematical models (3).

In low-income countries, like Malawi, important public health measures like social distancing or a lockdown, are difficult to implement owing to socioeconomic constraints. Furthermore, the limited capacity to test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection impedes effective public health response planning. Initial testing in Malawi focused on case identification in patients with COVID-19-like symptoms, contacts of index patients and inbound travellers. The first COVID-19 case in Malawi was reported on 2nd April and as of 16th July 2020 there were 2716 cases with only 51 deaths reported (2, 4). Given the sampling strategy, the true burden is certainly much greater than the reported cases, but there are no reliable estimates of the true burden of infection and death. Up to now, health services have reported only small number of cases and have not been overwhelmed as predicted (3).

The unrestricted nature of the COVID-19 epidemic in Malawi provides an opportunity to compare its trajectory in a low-income setting with what has been reported in high income settings. It has been shown that the rate of asymptomatic SARS-CoV-2 infection among Health Care Workers (HCW) reflects general community transmission rather than in-hospital exposure (5). We, therefore, conducted a SARS-CoV-2 serosurvey amongst HCW in

100 Blantyre city to estimate the cumulative incidence of SARS-CoV-2 infection in urban
101 Malawi.
102
103 **Methods**
104 **Study participants**
105 The study was conducted at the Malawi-Liverpool-Wellcome Trust Clinical Research
106 programme in Blantyre, Malawi, between 22nd May 2020 to 19th June 2020. Participants were
107 HCWs from Blantyre City, both clinical and non-clinical. Inclusion criteria for the study
108 included being HCW resident in Blantyre, aged between 18 and 65 years old, and otherwise
109 symptomatic. The exclusion criterion was withholding consent. Ethical approval was
110 provided by the College of Medicine Research and Ethics Committee (COMREC, Malawi)
111 (P.05/20/3045) and Liverpool School of Tropical Medicine (LSTM, UK) (20-043).
112
113 **Sample collection, processing and experimental setup**
114 Peripheral blood samples were collected from all study participants in serum separation tubes
115 (SST) (BD Biosciences). Serum was collected from the SSTs and stored at -80ºC for storage.
116 To measure SARS-CoV-2 antibodies, we used a commercial Enzyme Linked-Immunosorbent
117 Assay (ELISA) targeting Spike (S2) and Nucleoprotein (N) from SARS-CoV-2 (Omega
118 diagnostics, UK). The assay was performed as per manufacturer's instructions. This assay has
119 undergone rigorous independent validation at the Liverpool School of Tropical Medicine
120 (UK) and St George's University of London (UK) (6).
121
122 **Statistical analysis**
123 Graphical presentation were performed using GraphPad Prism 8 (GraphPad Software, USA).
124 We used FlowJo v10 software (Treestar, USA) to analyse flow cytometry data. To integrate

uncertainty arising from test sensitivity and specificity, we used a Bayesian model to produce a posterior distribution of seroprevalence that incorporates uncertainty associated with a finite sample size (7). The geospatial data was plotted using using RStudio (Version 1.3.959).

Results

Demographics of study participants

We recruited 500 asymptomatic HCW median age 31 (range 20-64 years). The average household size for the participants was 4 [Confidence Interval (CI) 3–5]. Three hundred and thirty-one were clinical HCWs and 169 non-clinical HCWs (**Table 1**). The clinical HCWs included nurses, medical doctors and clinical officers, while the non-clinical HCWs included clerical/administration, field workers and laboratory scientists. The primary workstation for the HCW included primary healthcare facility (35/500), secondary healthcare facility (291/500), and clinical research facility (174/500). The majority of the participants were nurses (57%). Forty one percent of all participants were involved in clinical work related to COVID-19 and 73% of the total participants used public transport or walking as main means of transport. The average household size for the participants was 4[CI 3-5]. The main characteristics of the participants are summarised in **Table 1**.

Seroprevalence of SARS CoV-2 antibodies and geospatial location of the antibody positive individuals

Using historical control samples from Malawi (2018–2019), which included malaria convalescence sera and sera from asymptomatic HIV-infected adults (antiretroviral therapy (ART) naïve and those on ART), we determined local assay cut-offs for seropositivity, low cut-off [+20% above manufacturer's cut-off value], and conservative high cut-off (+80% above manufacturer's cut-off value). The highest false positive sample was from an

150 asymptomatic HIV-uninfected adult collected end August 2019. None of the false positive
151 samples were malaria convalescence sera. The assay specificity at the low cut-off was 93%
152 (82/88) [88-96] and 97% (85/88) [90-99] at the high conservative high cut-off.
153
154 Eighty-four participants tested positive for SARS-CoV-2 antibodies at the local low cut-off,
155 while 39 participants tested positive for SARS-CoV-2 antibodies at the local conservative
156 high cut-off (**Figure 1** and **Table 1**). After adjusting for test sensitivity and specificity, the
157 overall seroprevalence of SARS-CoV-2 antibodies was 12.3% [CI 9.0–15.7] at low cut-off
158 and 5.9% [CI 3.6–8.3] at conservative high cut-off. This suggests that local transmission was
159 high and that SARS-CoV-2 may have been circulating for some time in Blantyre.
160
161 To estimate the potential geographical spread of SARS-CoV-2, we plotted the geographical
162 coordinates of place of residence for the individuals with a positive antibody on the map of
163 Blantyre City. We found that the HCW with a positive SARS-CoV-2 antibody result came
164 from different parts of the city (**Figure 2**). This suggests that SARS-CoV-2 local transmission
165 was widespread across the city.
166
167 **Crude projections of mortality based on seroprevalence estimates**
168 Using estimates of infection fatality rates from Verity *et al.* (8) and the Malawi population
169 census (9), we estimated the number of deaths that could have occurred at the observed
170 seroprevalence of SARS-CoV-2 antibodies **(Table 2)**. We adjusted the population estimates
171 by inflating them to take into account population annual population growth rate of 2% from
172 2018 to 2020 (9). We assumed that there was a uniform risk of infection at all age groups and
173 that the seroprevalence was similar to the general population.
174

The crude estimates suggest that there should have been at least 138 deaths by 19th June 2020. However, four weeks following the serosurvey, only 17 COVID-confirmed deaths in Blantyre have been reported by the Public Health Institute of Malawi (4), which is approximately 8 times below the predicted deaths. When the seroprevalence is extrapolated to the entire Malawi, it predicts approximately 5,295 COVID-19 deaths, but only 51 deaths have been reported by 16th July 2020. These crude estimates highlight a discrepancy between the predicted deaths using infection fatality rates from elsewhere and the actual number of reported COVID-19 deaths in Malawi.

Conclusions

To our knowledge, this seroprevalence study among HCW is among the first to report estimates of SARS-CoV-2 exposure in an African urban low-income setting. It provides insights into the potentially unique trajectory of the COVID-19 epidemic in sub-Saharan Africa (SSA), using data from urban Malawi. We observe a high seroprevalence of SARS-CoV-2 antibodies amongst HCW. It has been reported elsewhere that HCW accounted for a high proportion of cases early in the SARS-CoV-2 outbreak when transmission was increasing sharply and personal protective equipment (PPE) provision was patchy (10-12). Our data could suggest that Malawi is relatively early in the epidemic and that COVID-19 cases are likely to continue to rise sharply in the coming weeks, but the serology also suggests that large numbers of cases must be either asymptomatic or only show mild disease.

The discrepancy between the predicted compared reported mortality at the observed seroprevalence estimate, may also suggest that there are large numbers of underreported or misclassified deaths in Malawi. However, even in countries like South Africa with relatively abundant testing capacity and strong health systems there is relatively low mortality with a

200 case fatality ratio of 1.5 (13). This may imply that the impact of SARS-CoV-2 in Africa is
201 potentially much less severe or is following a different trajectory than that experienced in
202 China, Americas and Europe, where case fatality ratios were commonly above 5 (1). This
203 warrants further investigation.
204
205 However, the reasons behind the discrepancy in the COVID-19 pandemic trajectory between
206 SSA and elsewhere might include population demography, climate and prior cross-reactive
207 immunity (14). In Malawi, for example, the population is younger (median age 17 years old)
208 (9), and the elderly who mostly experience worse outcomes in other settings (8), are 5.1% of
209 the population (9), largely residing in rural areas. If the prevalence of SARS-CoV-2 is very
210 low in rural areas, this may explain the low number of deaths, and would strengthen the call
211 to shield the elderly (15).
212
213 This study has some limitations. First, selection bias is likely due to the convenience
214 sampling approach, however, targeting HCW for regular serosurveys could help predict local
215 transmission outbreaks. Second, this serosurvey focused on an urban population where
216 Malawi has reported the concentration of COVID-19 cases. The seroprevalence in the rural
217 population remains unknown, but if high, may prompt other explanations for the
218 African/Malawi situation. Third, current SARS-CoV-2 ELISAs are still undergoing rigorous
219 validation and verification in the African settings, hence seroprevalence estimates could
220 change with new information on the accuracy of the test kits.
221
222 In conclusion, our findings indicate a major discrepancy between predicted COVID-19
223 mortality at the observed SARS-CoV-2 seroprevalence in HCW, with reported COVID-19
224 deaths in urban Malawi. The high seroprevalence estimate implies earlier exposure of SARS-

CoV-2 than that reported but with slow progression of the COVID-19 epidemic. Development of locally parameterised mathematical models should be prioritised to more accurately predict the trajectory of the epidemic in SSA. This will allow better evidence-based policy decision-making and public health response planning.

Acknowledgements

We acknowledge the PROTECT Study Team at the Malawi-Liverpool-Wellcome Trust Clinical Research Programme, namely Alice Kalilani, Gift Sagawa, Martha Moyo, Orpha Kumwenda, Sharon Nthala, Chisomo Jassi, Neema Nyakuleha and Tayamika Banda. We thank Dr Joe Fitchett at Mologic (UK) for providing the SARS-CoV-2 ELISA kits.

Funding

This work was funded by the Wellcome (UK), NIHR (UK), MRC (UK) and NIH (USA). K.C.J* was supported by the NIHR and MRC through grant numbers 3477609 and MR/T008822/1, respectively. K.C.J.[§] was supported by a Wellcome Training Fellowship number 201945/Z/16/Z. M.G.C. is supported by NIH through grant number U01AI131348. E.R.A is supported by the Wellcome Trust/DFID Joint Initiative for Research in Epidemic Preparedness and Response (220764/Z/20/Z), and the NIHR HPRU (200907) in Emerging and Zoonotic Infection. The Malawi-Liverpool-Wellcome Trust Clinical Research Programme [MLW] was supported by a strategic award from the Wellcome awarded to S.B.G.

Author Contributions

K.C.J. *, K.C.J. [§], M.G.C., A.M. and S.B.G. conceived and designed the study. M.G.C, S.M., N.M. and S.S. collected clinical data and blood samples. R.K., J.M., D.T., L.S., P.M., I.K.

and A.L. performed the laboratory work. K.C.J.* carried out the statistical analyses. K.C.J.*, K.CJ. [§], M.G.C. and S.B.G. drafted the manuscript. K.C.J*., K.C.J. [§], M.G.C. and S.B.G. obtained funding for the study. All authors contributed to critical revision of the manuscript for important intellectual content*:* All authors have read and approved the final manuscript.

Disclaimer

The funders had no role in the study design, data collection and interpretation, or the decision to submit the work for publication. Mologic (UK) was provided the opportunity to review a preliminary version of this manuscript for factual accuracy but the authors are solely responsible for final content and interpretation. The authors received no financial support or other form of compensation related to the development of the manuscript. The findings and conclusions in this report are those of the authors.

Potential conflicts of interest

E.R.A. and R.L.B. worked with Mologic (UK) to independently validate the SARS-CoV-2 ELISA at the Liverpool School of Tropical Medicine (LSTM). All other authors report no potential conflicts.

.

Figure Legends

Figure 1. SARS-CoV-2 serological results from asymptomatic health care workers. We used a commercial ELISA to measure SARS-CoV-2 antibodies against Spike (S2) and Nucleoprotein (N). We run the assay on local negative control samples from 2018 to 2019 and used the results to set assay cut off values for positivity. These cut-off values were then used to interpret results from our test samples. OD, Optical Density.

Figure 2. Map of Blantyre showing geospatial distribution of seropositive results. We collected geocoordinate data for the place of residence of all study participants at recruitment. The geocoordinates were combined with the ELISA assay results based on the low local assay cut-off and plotted on the map of Blantyre using R. Black dot, seronegative; Orange dot, indeterminate; Red dot, seropositive.

294 **References**

295 1. JHU. COVID-19 Case Tracker 2020 [cited; Available from:
296 https://coronavirus.jhu.edu/map.html.
297 2. CDC A. Latest updates on the COVID-19 crisis from Africa CDC. 2020 [cited 2020
298 15.07.2020]; Available from:
299 3. Walker PGT, Whittaker C, Watson OJ, Baguelin M, Winskill P, Hamlet A, et al. The
300 impact of COVID-19 and strategies for mitigation and suppression in low- and middle-
301 income countries. Science. 2020 Jun 12.
302 4. PHIM. Daily COVID--19 Situation Report. Lilongwe: Public Health Institute of
303 Malawi, Ministry of Health; 2020 1st July 2020.
304 5. Treibel TA, Manisty C, Burton M, McKnight A, Lambourne J, Augusto JB, et al.
305 COVID-19: PCR screening of asymptomatic health-care workers at London hospital.
306 Lancet. 2020 May 23;395(10237):1608-10.
307 6. Adams ER, Augustin Y, Byrne RL, Clark DJ, Cocozza M, Cubas-Atienzar AI, et al.
308 Rapid development of COVID-19 rapid diagnostics for low resource settings:
309 accelerating delivery through transparency, responsiveness, and open collaboration.
310 medRxiv. 2020.
311 7. Larremore DB, Fosdick BK, Bubar KM, Zhang S, Kissler SM, Metcalf CJE, et al.
312 Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with
313 uncertainty from serological surveys. medRxiv. 2020.
314 8. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of
315 the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis.
316 2020 Jun;20(6):669-77.
317 9. NSO. 2018 Malawi Population and Housing. Zomba: National Statistical Office,
318 Government of Malawi; 2019.

319 10. Lai X, Wang M, Qin C, Tan L, Ran L, Chen D, et al. Coronavirus Disease 2019
320 (COVID-2019) Infection Among Health Care Workers and Implications for Prevention
321 Measures in a Tertiary Hospital in Wuhan, China. JAMA network open. 2020 May
322 1;3(5):e209666.
323 11. Kluytmans-van den Bergh MFQ, Buiting AGM, Pas SD, Bentvelsen RG, van den
324 Bijllaardt W, van Oudheusden AJG, et al. Prevalence and Clinical Presentation of Health
325 Care Workers With Symptoms of Coronavirus Disease 2019 in 2 Dutch Hospitals During
326 an Early Phase of the Pandemic. JAMA network open. 2020 May 1;3(5):e209673.
327 12. Cheng VC, Wong SC, Yuen KY. Estimating Coronavirus Disease 2019 Infection
328 Risk in Health Care Workers. JAMA network open. 2020 May 1;3(5):e209687.
329 13. Government SA. Update on Covid-19. 2020 [cited; Available from:
330 https://sacoronavirus.co.za
331 14. Njenga MK, Dawa J, Nanyingi M, Gachohi J, Ngere I, Letko M, et al. Why is There
332 Low Morbidity and Mortality of COVID-19 in Africa? The American journal of tropical
333 medicine and hygiene. 2020 Jun 1.
334 15. Divala T, Burke RM, Ndeketa L, Corbett EL, MacPherson P. Africa faces difficult
335 choices in responding to COVID-19. Lancet. 2020 May 23;395(10237):1611.
336

Table 1. Study participant demographics

Characteristics	Number of participants	Proportion
Gender		
Male	236	47%
Female	264	53%
Age		
20-29	209	42%
30-39	170	34%
40-49	86	17%
50-59	28	6%
60+	7	1
Occupation		
Clinical HCW	331	66%
Non-Clinical HCW	169	34%
COVID-19 work		
Clinical	205	41%
Non-Clinical	43	9%
None	252	50%
Transport		
Public + Walking	363	73%
Private	137	27%

COVID-19, Coronavirus Diseases of 2019; HCW, Health Care Workers

Table 1. Number of projected deaths relative to SARS-CoV-2 seroprevalence in Blantyre and Malawi

Age	Population* (Blantyre)	Population* (Malawi)	Infection fatality rate ✝	Number of Infections		Deaths	
				Blantyre	Malawi	Blantyre	Malawi
0-9 yrs	207,002	5,394,769	0.00%	24,840	663,557	0	11
10-19 yrs	199,915	4,753,846	0.01%	23,990	584,723	2	41
20-29 yrs	176,360	2,997,379	0.03%	21,163	368,678	7	114
30-39 yrs	130,362	2,160,103	0.08%	15,643	265,693	13	224
40-49 yrs	67,618	1,316,593	0.16%	8,114	161,941	13	261
50-59 yrs	28,397	722,800	0.60%	3,408	88,904	20	529
60-69 yrs	15,225	494,678	1.93%	1,827	60,845	35	1,174
70-79 yrs	5,715	280,394	4.28%	686	34,488	29	1,476
80+ yrs	2,001	152,762	7.80%	240	18,790	19	1,466
Total	**832,595**	**18,273,324**		**99,911**	**2,247,619**	**138**	**5,295**

*2018 Population and Housing Census. ✝ estimates derived from Verity, R. et al. 2020.



Figure 1. SARS CoV-2 serological results from asymptomatic health care workers



Black dot, negative; Red dot, positive; Orange dot, indeterminate

Figure 2. Map of Blantyre showing geospatial distribution of seropositive results using the low local assay cut-off